Effect of omeprazole on liver functions of laboratory rat (albino) Rattus norvegicus

Paper Details

Research Paper 01/06/2018
Views (319) Download (14)

Effect of omeprazole on liver functions of laboratory rat (albino) Rattus norvegicus

Suhad Yasin Jassim, Rabab Abd Alameer Nasser
Int. J. Biosci.12( 6), 123-128, June 2018.
Certificate: IJB 2018 [Generate Certificate]


First, the aim of this work was to determine and estimate the effect of Omeprazole drug on liver function in the laboratory rat (Albino) Rattus norvegicus by measuring the concentration of alanin aminotransferase (GPT) and aspartate aminotransferase (GOT) enzymes, (18) animals aged (6) weeks and weight of (40-60) g were selected randomly from the animal house of our work place,They were divided into three groups: the first one was administrated (20) mg/kg of drug, second group was given (40) mg/kg and the third group was the control (non treated).The statistical analysis used in this study is the variance analysis test (ANOVA) at (p˂ 0.05) level. After giving medication to animals regularly for three consecutive months without interruption,GPT and GOT enzymes tests were measured and the following results were obtained:Significant increase was observed in the concentration of the GPT enzyme for the second group (40) mg/kg at p˂ 0.05 (43.1167)I u/lcompared with the control group (26.4350) I u/l, while there was no significant difference between the first group (20) mg/kg and the control. As for the GPT test; a significant increase was observed for both dosage groups (20) & (40) mg/kg respectively at p˂ 0.05 (116.7417) (68.9050) I u/l compared with control group (63.5083) I u/l. From the above results it can be confirmed that the long-term use of Omeprazole leads to an imbalance in liver enzymes and this will damage its functions thus this damage will be transmitted to all organs of the body.


Jassim SY, HussinAM.2017. The Effect of Omeprazole Drug on the Blood Picture of Laboratory Rat Rattus Norvegicus, IOSR Journal of Pharmacy and Biological Sciences, Volume 12, Issue 3 Ver. IV, PP 56-59.

Hasanin A H. .2014 Impact of omeprazole on bone remodeling in normal and ovariectomized Wistar rats. Eur Rev Med PharmacolSci, Jul;18(13), 48-56.

Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P.1990. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole, Clin Pharmacol Ther, Jan; 47(1), 79-85.

Cederberg C, Andersson T, Skånberg I. 1989. Omeprazole.Pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl.166,33-40.

Hamada H, Ohkura Y.1976. A new photometric method for the determination of serum glutamate pyruvate transaminase activity using pyruvate and glutamate as substrates. Chem. Pharm. Bull.; 24, 1865–1869.

Moser I, Jobst G, Svasek P, Varahram M, Urban G.1997.Rapid liver enzyme assay with miniaturized liquid handling system comprising thin film biosensor array. Sens. Actuators B,44,377–380.

Xing-Jiu Huang, Yang-Kyu Choi, Hyung-Soon Im, Oktay Yarimaga, Euisik Yoon, and Hak-Sung Kim. 2006. Sensors (Basel). Jul; 6(7),756–782.

Koolhaas JM. 2010. The UFAW Handbook on the Care and Management of Laboratory  and Other Research Animals (Eighth Edition Hubrecht, R. & Kirkwood, J. (eds.). s.n.,) 311-326.

Segal HL, Matsuzawa TL. 1970. Alanine aminotransferase (rat liver). Methods in Enzymology 17A,153-159.

Itoh H, Srere PA.1970. A new assay for glutamate-oxaloacetate transaminase Anal. Biochem. 35,405–410.

Schumann G, Bonora R, Ceriotti F, Férard G, Ferrero CA, Franck PFH, Gella FJ, Hoelzel W, Jørgensen PJ, Kanno T, Kessner A, Klauke R, Kristiansen N, Lessinger JM, Linsinger TP, Misaki H, Panteghini M, Pauwels J, Schiele F, Schimmel HG, Weidemann G, Siekmann L. 2002. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C: Part 5. Reference procedure for the measurement of catalytic concentration of aspartate-aminotransferase. Clin. Chem. Lab Med.; 40,725–733.

McDonald JH. 2014. Handbook of Biological Statistics (3rd ed.). Sparky House Publishing, Baltimore.

Jin Bian MD, Anqiang Wang MD, Jianzhen Lin MD, Liangcai Wu MD, Hanchun Huang, MD, Shanshan Wang MD, Xiaobo Yang, MD, Xin Lu, MD, YiyaoXu MD, Haitao Zhao, MD. 2017. Association between proton pump inhibitors and hepatic encephalopathy A meta-analysis Apr; 96(17),e6723.

Francavilla A, Panella C, Polimeno L, Di Leo A, Makowka L, Baronel M, Amoruso A, Ingrosso M, Starz TE. 1989. Effect of cimetidine, ranitidine, famotidine and omeprazole on hepatocyte proliferation in vitro, Journal of Hepatology8,32-41, Elsevier.

Cheng E. 2013.Proton Pump Inhibitors for Eosinophilic Esophagitis, current Opinion in Gastroenterology. 29(4),416–420.

Kinuthia E. 2017: Omeprazole Liver Side Effects, Liver strong.com.

Regårdh CG, Gabrielsson M, Hoffman KJ, Löfberg I, Skånberg I. 1985.     Pharmacokinetics and metabolism of omeprazole in animals and man–an overview. Scand J Gastroenterol Suppl.108, 79-94.

Ray Kim W, Steven L,Flamm Adrian M, Di Bisceglie. 2008. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease, Hepatology, 47(7),1363-1370.

Sauvet P, Schouler L. 1992 Omeprazole and liver function,Rev Med Interne. Sep-Oct; 13(5):359-63. Review. French.

Li W, Zeng S, Yu LS, Zhou Q. 2013Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag 9,259–271.

George A, Zobair MY.2010, When and how to evaluate mildly elevated liver enzymes in apparently healthy patients, C level and Clinic Journal of Medicine 7(7).

HenryC, Bodenheimer Jr. 2008: Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease 47(4), 1363–1370.